Analyst Reco. Revolution Medicines, Inc.

Stocks

RVMD

US76155X1000

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 17/06/2026 BST			After hours 00:56:51
157.77 ^USD	+0.76%		160.16	+1.51%

06-08	Top Midday Gainers	MT
06-08	Top Midday Stories: US Weighs Financial Stakes in AI Firms; Google, Nvidia Turn to Intel as TSMC Struggles With Demand	MT

Analyst Reco.

06-02	Revolution Medicines' Cancer Drug Darax Seen Holding Lead Over Rivals, RBC Says	MT
06-02	RBC Raises Price Target on Revolution Medicines to $182 From $165, Keeps Outperform, Speculative Risk	MT
06-01	Revolution Medicines' Trial Data Shows Daraxonrasib is 'Winner' in Pancreatic Cancer Treatment, RBC Says	MT
06-01	Oppenheimer Adjusts Revolution Medicines PT to $195 From $165, Maintains Outperform Rating	MT
05-22	Bernstein Initiates Revolution Medicines at Market Perform	MT
05-07	RBC Capital Adjusts Revolution Medicines Price Target to $165 From $162, Maintains Outperform Speculative Risk Rating	MT
05-07	Wedbush Raises Price Target on Revolution Medicines to $165 From $147, Keeps Outperform Rating	MT
04-23	Mizuho Raises Price Target on Revolution Medicines to $185 From $140, Keeps Outperform Rating	MT
04-20	UBS Adjusts Price Target on Revolution Medicines to $175 From $145, Maintains Buy Rating	MT
04-14	Revolution Medicines Facing Further Upside After Daraxonrasib's Results, RBC Says	MT
04-14	RBC Raises Price Target on Revolution Medicines to $162 From $140, Keeps Outperform, Speculative Risk	MT
03-30	Revolution Medicines' Readout of Trial for Pancreatic Cancer Drug Likely Positive, Oppenheimer Says	MT
02-27	Revolution's Daraxonrasib has 'Blockbuster' Potential, UBS Says	MT
02-27	UBS Adjusts Revolution Medicines Price Target to $145 From $71, Maintains Buy Rating	MT
02-27	Truist Adjusts Price Target on Revolution Medicines to $116 From $99, Maintains Buy Rating	MT
02-27	Truist Raises Price Target on Revolution Medicines to $116 From $99, Keeps Buy Rating	MT
02-26	Mizuho Trims Price Target on Revolution Medicines to $140 From $143, Keeps Outperform Rating	MT
01-21	RBC Boosts Price Target on Revolution Medicines to $140 From $77, Keeps Outperform, Speculative Risk	MT
01-13	Mizuho Adjusts Price Target on Revolution Medicines to $143 From $90, Maintains Outperform Rating	MT
01-09	Wedbush Raises Price Target on Revolution Medicines to $147 From $80, Keeps Outperform Rating	MT
01-06	BofA Adjusts Price Target on Revolution Medicines to $98 From $82, Maintains Buy Rating	MT
11-06	Wedbush Lifts Price Target on Revolution Medicines to $80 From $77, Keeps Outperform Rating	MT
11-03	Revolution Medicines is Best-Positioned to Execute Targeting RAS-Mutated Cancers, RBC Says	MT
11-03	RBC Initiates Revolution Medicines at Outperform, Speculative Risk With $77 Price Target	MT
21/10/25	Mizuho Initiates Revolution Medicines at Outperform With $90 Price Target	MT